Single-Agent Rovalpituzumab Tesirine, a Delta-Like Protein 3 (DLL3)-Targeted Antibody-Drug Conjugate (ADC), in Small-Cell Lung Cancer (SCLC)

被引：1

作者：

Spigel, David ^{[1
]}

Pietanza, M. Catherine ^{[2
]}

Bauer, Todd ^{[1
]}

Ready, Neal ^{[3
]}

Morgensztern, Daniel ^{[4
]}

Glisson, Bonnie S. ^{[5
]}

Byers, Lauren Averett ^{[5
]}

Johnson, Melissa ^{[1
]}

Burris, Howard ^{[1
]}

Robert, Francisco ^{[6
]}

Han, Tae ^{[7
]}

Bheddah, Sheila ^{[7
]}

Theiss, Noah ^{[8
]}

Watson, Sky ^{[8
]}

Mathur, Deepan ^{[8
]}

Vennapusa, Bharathi ^{[8
]}

Strickland, Donald ^{[1
]}

Zayed, Hany ^{[7
]}

Dylla, Scott ^{[7
]}

Peng, Stanford ^{[7
]}

Govindan, Ramaswamy ^{[4
]}

Rudin, Charles ^{[9
]}

机构：

[1] Tennessee Oncol PLCC, Sarah Cannon Res Inst, Nashville, TN USA

[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[3] Duke Univ, Med Ctr, Durham, NC USA

[4] Washington Univ, Sch Med, St Louis, MO USA

[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[6] Univ Alabama Birmingham, Birmingham, AL USA

[7] Abbvie Stemcentrx Llc, San Francisco, CA USA

[8] Roche Diagnost, Tucson, AZ USA

[9] Mem Sloan Kettering Canc Ctr, Med, 1275 York Ave, New York, NY 10021 USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期

关键词：

clinical trial; Rovalpituzumab tesirine; Delta-like protein 3; SCLC;

D O I：

10.1016/j.jtho.2016.11.252

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OA05.03

引用

页码：S260 / S261

页数：2

共 48 条

[1] Safety, activity, and response durability assessment of single agent rovalpituzumab tesirine, a delta-like protein 3 (DLL3)-targeted antibody drug conjugate (ADC), in small cell lung cancer (SCLC)
Pietanza, M. C.
Spigel, D.
Bauer, T. M.
Ready, N. E.
Glisson, B. S.
Morgensztern, D.
Robert, F.
Salgia, R.
Kochendorfer, M.
Patel, M.
Strickland, D. K.
Govindan, R.
Burris, H. A.
Rudin, C. M.
Dylla, S.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S712 - S712
[2] Rovalpituzumab tesirine Antibody-drug conjugate targeting delta-like protein 3 (DLL3) Treatment of small cell lung cancer
Gras, J.
DRUGS OF THE FUTURE, 2018, 43 (04) : 261 - 265
[3] Safety and efficacy of single-agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC) in recurrent or refractory small cell lung cancer (SCLC).
Rudin, Charles M.
Pietanza, Maria Catherine
Bauer, Todd Michael
Spigel, David R.
Ready, Neal
Morgensztern, Daniel
Glisson, Bonnie S.
Byers, Lauren Averett
Johnson, Melissa Lynne
Burris, Howard A.
Robert, Francisco
Strickland, Donald K.
Zayed, Hany
Govindan, Ramaswamy
Dylla, Scott
Peng, Stanford L.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (18)
[4] Metastatic melanoma, glioblastoma and high-grade extrapulmonary neuroendocrine carcinomas (NECs) as novel indications for rovalpituzumab tesirine: A delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC).
Peng, Stanford L.
Saunders, Laura
Bheddah, Sheila
Williams, Sam
Aggarwal, Rahul Raj
Shea, Jill E.
Lee, Eun Y.
Huang, Jiaoti
Zemek, Allison J.
Longacre, Teri A.
Ball, Douglas Wilmot
Scaife, Courtney L.
Nelkin, Barry
Anthony, Lowell Brian
Kunz, Pamela L.
Small, Eric Jay
Dylla, Scott
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[5] Rovalpituzumab tesirine and DLL3: a new challenge for small-cell lung cancer
Rossi, Antonio
LANCET ONCOLOGY, 2017, 18 (01): : 3 - 5
[6] Safety and Efficacy of Single-Agent Rovalpituzumab Tesirine, a DLL3-Targeted ADC, in Recurrent or Refractory SCLC
Bauer, Todd M.
Spigel, David
Ready, Neal
Morgensztern, Daniel
Glisson, Bonnie S.
Byers, Lauren A.
Burris, Howard
Robert, Francisco
Strickland, Donald K.
Pietanza, Maria C.
Govindan, Ramaswamy
Dylla, Scott J.
Peng, Stanford
Rudin, Charles
JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) : S252 - S253
[7] Expression of DLL3 in metastatic melanoma, glioblastoma and high-grade extrapulmonary neuroendocrine carcinomas as potential indications for rovalpituzumab tesirine (Rova-T; SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody drug conjugate (ADC)
Saunders, Laura R.
Williams, Samuel A.
Bheddah, Sheila
Isse, Kumiko
Fong, Sarah
Pysz, Marybeth A.
Beltran, Himisha
Puca, Loredana
Sailer, Verena
Mosquera, Juan M.
Yin, Yu
Huang, Jiaoti
Armstrong, Andrew J.
Garcia, Jorge
Magi-Galluzzi, Cristina
Koshkin, Vadim
Grivas, Petros
Kosari, Farhad
Cheville, John
Moser, Justin C.
Flotte, Thomas J.
Halfdanarson, Thorvardur
Mansfield, Aaron
Leventakos, Konstantinos N.
Molina, Julian R.
Ball, Douglas W.
Nelkin, Barry D.
Shea, Jill E.
Scaife, Courtney L.
Dylla, Scott J.
CANCER RESEARCH, 2017, 77
[8] lePopulation pharmacokinetics of rovalpituzumab tesirine, an antibody-drug conjugate, in phase I and II studies of small-cell lung cancer
Stodtmann, Sven
Freise, Kevin
Beck, Denise
Mensing, Sven
Liu, Wei
Kosloski, Matthew P.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2018, 45 : S78 - S79
[9] Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer
Charles M. Rudin
Martin Reck
Melissa L. Johnson
Fiona Blackhall
Christine L. Hann
James Chih-Hsin Yang
Julie M. Bailis
Gwyn Bebb
Amanda Goldrick
John Umejiego
Luis Paz-Ares
Journal of Hematology & Oncology, 16
[10] Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer
Rudin, Charles M. M.
Reck, Martin
Johnson, Melissa L. L.
Blackhall, Fiona
Hann, Christine L. L.
Yang, James Chih-Hsin
Bailis, Julie M. M.
Bebb, Gwyn
Goldrick, Amanda
Umejiego, John
Paz-Ares, Luis
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2023, 16 (01)

← 1 2 3 4 5 →